Human Genome Epidemiology Literature Finder
Records 1 - 30 (of 36 Records) |
Query Trace: Depressive Disorder and CYP2D6[original query] |
---|
Increased carrier prevalence of deficient CYP2C9, CYP2C19 and CYP2D6 alleles in depressed patients referred to a tertiary psychiatric hospital. Personalized medicine 2008 Nov 5 (6): 579-587. Ruaño Gualberto, Villagra David, Rahim Umme Salma, Windemuth Andreas, Kocherla Mohan, Bower Bruce, Szarek Bonnie L, Goethe John |
Severe sleepiness and excess sleep duration induced by paroxetine treatment is a beneficial pharmacological effect, not an adverse reaction. Journal of affective disorders 2013 Sep 150 (3): 1209-12. Murata Yusuke, Kamishioiri Yuko, Tanaka Kenji, Sugimoto Hiroko, Sakamoto Shoko, Kobayashi Daisuke, Mine Kazuno |
Length of psychiatric hospitalization is correlated with CYP2D6 functional status in inpatients with major depressive disorder. Biomarkers in medicine 2013 Jun 7 (3): 429-39. Ruaño Gualberto, Szarek Bonnie L, Villagra David, Gorowski Krystyna, Kocherla Mohan, Seip Richard L, Goethe John W, Schwartz Harold |
CYP2D6 P34S Polymorphism and Outcomes of Escitalopram Treatment in Koreans with Major Depression. Psychiatry investigation 2013 Sep 10 (3): 3. Han KM, Chang HS, Choi IK, Ham BJ, Lee MS |
An observational study of Venlafaxine and CYP2D6 in clinical practice. Clinical laboratory 2014 60 (2): 225-31. Rolla R, Gramaglia Carla, Dalò Valentina, Ressico Francesca, Prosperini Pierluigi, Vidali Matteo, Meola Silvia, Pollarolo Paola, Bellomo Giorgio, Torre Eugenio, Zeppegno Patriz |
Citalopram and escitalopram plasma drug and metabolite concentrations: genome-wide associations.
British journal of clinical pharmacology 2014 Aug 78 (2): 373-83. Ji Yuan, Schaid Daniel J, Desta Zeruesenay, Kubo Michiaki, Batzler Anthony J, Snyder Karen, Mushiroda Taisei, Kamatani Naoyuki, Ogburn Evan, Hall-Flavin Daniel, Flockhart David, Nakamura Yusuke, Mrazek David A, Weinshilboum Richard |
Influence of the cytochrome P450 2D6 *10/*10 genotype on the pharmacokinetics of paroxetine in Japanese patients with major depressive disorder: a population pharmacokinetic analysis. Pharmacogenetics and genomics 2016 May . Nishimura Miki, Ueda Mikito, Saruwatari Junji, Nakashima Hiroo, Ogusu Naoki, Aoki Akiko, Tsuchimine Shoko, Matsuda Kazuki, Iwashita Kazuma, Ono Tatsumasa, Oniki Kentaro, Shimoda Kazutaka, Yasui-Furukori Nor |
Pharmacokinetics and Safety of Brexpiprazole Following Multiple-Dose Administration to Japanese Patients With Schizophrenia. Journal of clinical pharmacology 2018 Jan 58 (1): 74-80. Ishigooka Jun, Iwashita Shuichi, Higashi Koushi, Liew Ei Leen, Tadori Yoshihi |
Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder. Pharmacogenomics and personalized medicine 2018 11 113-119. Zastrozhin Mikhail Sergeevich, Grishina Elena Anatolievna, Denisenko Nataliya Petrovna, Skryabin Valentin Yurievich, Markov Dmitry Dmitrievich, Savchenko Ludmila Mikhailovna, Bryun Evgeny Alekseevich, Sychev Dmitry Alekseevi |
Genotype, phenotype, and medication recommendation agreement among commercial pharmacogenetic-based decision support tools. The pharmacogenomics journal 2018 5 18 (5): 613-622. Bousman Chad A, Dunlop Boadie |
Impact of CYP2D6 on venlafaxine metabolism in Trinidadian patients with major depressive disorder. Pharmacogenomics 2018 Jan . Montané Jaime Lazara Karelia, Paul Jeffrey, Lalla Anthony, Legall George, Gaedigk Andr |
Cytochrome P450 2C19 Poor Metabolizer Phenotype in Treatment Resistant Depression: Treatment and Diagnostic Implications. Frontiers in pharmacology 2019 3 10 83. Veldic Marin, Ahmed Ahmed T, Blacker Caren J, Geske Jennifer R, Biernacka Joanna M, Borreggine Kristin L, Moore Katherine M, Prieto Miguel L, Vande Voort Jennifer L, Croarkin Paul E, Hoberg Astrid A, Kung Simon, Alarcon Renato D, Keeth Nicola, Singh Balwinder, Bobo William V, Frye Mark |
Results of the CYP-GUIDES randomized controlled trial: Total cohort and primary endpoints. Contemporary clinical trials 2019 12 89 105910. Ruaño Gualberto, Robinson Saskia, Holford Theodore, Mehendru Raveen, Baker Seth, Tortora Joseph, Goethe John |
The Influence of Concentration of Micro-RNA hsa-miR-370-3p and CYP2D6*4 on Equilibrium Concentration of Mirtazapine in Patients With Major Depressive Disorder. Psychopharmacology bulletin 2020 8 50 (3): 58-75. Zastrozhin , Smirnov , Petukhov , Pankratenko , Zastrozhina , Grishina , Ryzhikova , Bure , Skryabin , Vlasovskih , Bryun , Syche |
Impact of Polymorphism of CYP2D6 on Equilibrium Concentration of Duloxetine in Patients Suffering from Major Depressive Disorder. Psychopharmacology bulletin 2020 8 50 (3): 47-57. Zastrozhin , Petukhov , Pankratenko , Grishina , Ryzhikova , Skryabin , Koporov , Bryun , Syche |
The Association of CYP2D6*4 and POR*28 Polymorphisms on Mirtazapine Plasma Level in Subjects with Major Depressive Disorder and Anxiety Disorders. Combinatorial chemistry & high throughput screening 2020 Apr . Ozdemir Fezile, Dural Emrah, Baskak Nilay Sedes, Kir Yagmur, Baskak Bora, Suzen H Sin |
Frequencies of Genetic Polymorphisms of Clinically Relevant Gene-Drug Pairs in a German Psychiatric Inpatient Population. Pharmacopsychiatry 2020 Dec . Hahn Martina, Müller Daniel J, Roll Sibylle |
Impact of CYP2D6 Polymorphism on Equilibrium Concentration of Fluoxetine in Patients Diagnosed With Major Depressive Disorder and Comorbid Alcohol Use Disorders. Journal of psychiatric practice 2021 Sep 27 (5): 372-379. Zastrozhin Mikhail S, Skryabin Valentin Y, Petukhov Alexey E, Pankratenko Ekaterina P, Grishina Elena A, Ryzhikova Kristina A, Torrado Marco V, Shipitsyn Valery V, Bryun Evgeny A, Sychev Dmitry |
Effects of Genetic Polymorphism in CYP2D6, CYP2C19, and the Organic Cation Transporter OCT1 on Amitriptyline Pharmacokinetics in Healthy Volunteers and Depressive Disorder Patients. Frontiers in pharmacology 2021 12 688950. Matthaei Johannes, Brockmöller Jürgen, Steimer Werner, Pischa Konstanze, Leucht Stefan, Kullmann Maria, Jensen Ole, Ouethy Typhaine, Tzvetkov Mladen Vassilev, Rafehi Muhamm |
Impact of the Omics-Based Biomarkers on the Mirtazapine's Steady-State Concentration, Efficacy and Safety in Patients with Affective Disorders Comorbid with Alcohol Use Disorder. Psychopharmacology bulletin 2021 6 51 (2): 31-42. Zastrozhin M S, Skryabin VYu, Smirnov VYu, Zastrozhina A K, Kaverina E V, Klepikov D A, Grishina E A, Ryzhikova K A, Bure I V, Bryun E A, Sychev D |
Effect of Genetic Polymorphism of the CYP2D6 Gene on the Efficacy and Safety of Fluvoxamine in Major Depressive Disorder. American journal of therapeutics 2021 Jun . Zastrozhin Michael, Skryabin Valentin, Smirnov Valeriy, Zastrozhina Anastasiya, Grishina Elena, Ryzhikova Kristina, Bure Irina, Golovinskii Pavel, Koporov Sergey, Bryun Evgeniy, Sychev Dmit |
Therapy response prediction in major depressive disorder: current and novel genomic markers influencing pharmacokinetics and pharmacodynamics. Pharmacogenomics 2021 5 22 (8): 485-503. Shalimova Alena, Babasieva Viktoria, Chubarev Vladimir N, Tarasov Vadim V, Schiöth Helgi B, Mwinyi Jessi |
Impact of the Omics-Based Biomarkers on the Fluvoxamine's Steady-State Concentration, Efficacy and Safety in Patients with Affective Disorders Comorbid with Alcohol Use Disorder. Psychopharmacology bulletin 2021 4 51 (1): 69-80. Zastrozhin M S, Skryabin VYu, Smirnov VYu, Zastrozhina A K, Kaverina E V, Klepikov D A, Grishina E A, Ryzhikova K A, Bure I V, Bryun E A, Sychev D |
Influence of Plasma Concentration of Hsa-Mir-370-3p and Cyp2d6*4 On Equilibrium Concentration of Phenazepam in Patients with Recurrent Depressive Disorder. Psychopharmacology bulletin 2021 12 51 (4): 87-104. Zastrozhin M S, Efimova A V, Skryabin VYu, Smirnov V V, Petukhov A E, Pankratenko E P, Pozdniakov S A, Kaverina E V, Klepikov D A, Grishina E A, Ryzhikova K A, Bure I V, Bryun E A, Sychev D |
Effects of CYP2D6*4 polymorphism on the steady-state concentration of paroxetine in patients diagnosed with depressive episode and comorbid alcohol use disorder. Journal of psychopharmacology (Oxford, England) 2022 7 36 (10): 1146-1150. Zastrozhin Mikhail, Skryabin Valentin, Petukhov Aleksey, Pankratenko Elena, Pozdniakov Sergei, Ivanchenko Valentina, Horyaev Denis, Vlasovskih Roman, Bryun Evgeny, Sychev Dmit |
Association of the Val66Met polymorphism of the BDNF gene and the deletional mutation of CYP2D6 gene with the prevalence and severity of depressive disorder in an Eastern Indian population. Indian journal of psychiatry 0 64 (3): 269-276. Haldar Somnath, Roy Suparna, Sen Santanu, Dasgupta Anindya, Ghosh Srij |
Effect of CYP2C19 Pharmacogenetic Testing on Predicting Citalopram and Escitalopram Tolerability and Efficacy: A Retrospective, Longitudinal Cohort Study. Biomedicines 2023 12 11 (12): . Mahmood Mahajna, Rami Abu Fanne, Matitiahu Berkovitch, Elias Tannous, Shlomo Vinker, Ilan Green, Ilan Mat |
Influence of CYP2C19, CYP2D6, and ABCB1 Gene Variants and Serum Levels of Escitalopram and Aripiprazole on Treatment-Emergent Sexual Dysfunction: A Canadian Biomarker Integration Network in Depression 1 (CAN-BIND 1) Study. Canadian journal of psychiatry. Revue canadienne de psychiatrie 2023 10 7067437231203433. Farhana Islam, Leen Magarbeh, Samar S M Elsheikh, Stefan Kloiber, Caroline W Espinola, Venkat Bhat, Benicio N Frey, Roumen Milev, Claudio N Soares, Sagar V Parikh, Franca Placenza, Stefanie Hassel, Valerie H Taylor, Francesco Leri, Pierre Blier, Rudolf Uher, Faranak Farzan, Raymond W Lam, Gustavo Turecki, Jane A Foster, Susan Rotzinger, Sidney H Kennedy, Daniel J Müll |
PBPK modeling to predict the pharmacokinetics of venlafaxine and its active metabolite in different CYP2D6 genotypes and drug-drug interactions with clarithromycin and paroxetine. Archives of pharmacal research 2024 4 . Chang-Keun Cho, Pureum Kang, Choon-Gon Jang, Seok-Yong Lee, Yun Jeong Lee, Jung-Woo Bae, Chang-Ik Ch |
CYP2D6 Genotyping and Inhibition as Predictors of Adverse Drug Reactions in Depressive Disorders. The Journal of clinical psychiatry 2024 1 85 (1): . Amanda Holck, Marie Asp, Henrik Green, Åsa Westrin, Margareta Re |
- Page last reviewed:Feb 1, 2024
- Page last updated:Jun 11, 2024
- Content source: